Comparative Pharmacology
Head-to-head clinical analysis: COLY MYCIN S versus POLYMYXIN B SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COLY MYCIN S versus POLYMYXIN B SULFATE.
COLY-MYCIN S vs POLYMYXIN B SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Colistin is a polymyxin antibiotic that binds to lipopolysaccharides in the outer membrane of Gram-negative bacteria, disrupting the membrane and causing cell death.
Polymyxin B sulfate binds to lipopolysaccharides (LPS) in the outer membrane of gram-negative bacteria, disrupting membrane integrity and causing cell death. It also has anti-endotoxin activity.
2.5 mg/kg/dose IV every 12 hours for 7-14 days (based on colistin base activity).
1.5 to 2.5 mg/kg/day IV divided every 12 hours; maximum 2.5 mg/kg/day. For topical use, apply 0.1% to 0.25% (10,000 to 25,000 units/g) ointment or cream 1-4 times daily.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours in normal renal function; prolonged in renal impairment (up to 24-48 hours in anuria).
Terminal elimination half-life is approximately 7-10 hours in adults with normal renal function. In patients with severe renal impairment (CrCl <30 mL/min), half-life may be prolonged to 2-3 days. Half-life is significantly extended in anuria (up to 48-72 hours). Clinically, dosing must be adjusted based on renal function and therapeutic drug monitoring is recommended.
Renal: ~70-80% unchanged via glomerular filtration; biliary/fecal: ~15-20% as active drug and metabolites.
Primarily renal excretion of unchanged drug via glomerular filtration (approx. 60-70% of a dose is recovered in urine as active polymyxin B). A smaller fraction (approximately 10-20%) is eliminated via non-renal pathways (biliary/fecal) as unchanged drug and minor metabolites; biliary excretion accounts for <5%.
Category C
Category C
Polymyxin Antibiotic
Polymyxin Antibiotic